At the World Vaccine Congress 2021, held May 4-6, leading research and industry partners discussed the challenges and trends in the evolving COVID-19 and vaccine development landscape. In this blog, we highlight our panel discussion with Sharon Benzeno, Chief Business Development Officer and our exhibitor seminar with Harlan Robins, Chief Scientific Officer & Co-founder.
Can adjuvants & immune profiling improve our immune response to current COVID vaccines?
Sharon Benzeno, Chief Business Development Officer, Adaptive Biotechnologies
Ofer Levy, Director, Precision Vaccines Program, Boston Children’s Hospital, Harvard Medical School
Tyler Martin, Chairman, President & CEO, Adjuvance Technologies
Alessandro Sette, Center Head, Division Head, & Professor, La Jolla Institute For Allergy & Immunology
Wolfgang Leitner, Chief Innate Immunity Section National Institute of Health-NIAID
T-cell immune response: Exploring emerging themes in vaccine development & COVID-19 variants
Harlan Robins, PhD, CSO & Co-founder, Adaptive Biotechnologies
Explore the cellular mechanisms underlying the response to SARS-CoV-2 with Dr. Harlan Robins, who discussed our data around COVID-19 and our work in the vaccine space. Watch on-demand now to find out more about how the immunoSEQ® Technology is driving discovery and insights in the field.
For Research Use Only. Not for use in diagnostic procedures.